Market Overview & Size

The global blood transfusion diagnostics market stood at USD 4.4 billion in 2022, moved to an estimated USD 4.7 billion in 2023, and is projected to reach USD 6.96 billion by 2030, expanding at a CAGR of 5.8% from 2023 to 2030, according to Grand View Research.

What makes this market worth watching isn't just the topline number — it's the shape of the curve. A 5.8% CAGR sitting on top of a multi-billion-dollar base means the market is adding roughly a quarter-billion dollars in fresh annual revenue by the back half of the forecast window, even though the growth rate itself looks modest next to flashier diagnostic categories like molecular oncology or genomics. That's the signature of an essential, low-churn healthcare category: blood transfusion diagnostics isn't a market that spikes and cools — it's infrastructure. Every hospital, blood bank, and diagnostic lab needs to keep testing every unit of donated blood, every single day, regardless of economic cycles. That structural stability is precisely why the category has stayed on a steady upward line even through a pandemic that briefly cut global blood donations.

Two forces are doing most of the heavy lifting behind this trajectory. First is disease burden: a Journal of Hematology and Oncology study cited in the report estimated 1,800 million anemia cases worldwide in 2019, while the U.S. alone reported roughly 490,875 leukemia patients in 2020 per National Cancer Institute data — both categories that routinely require transfusion support. Second is sheer transfusion volume: Ohio University research pegs daily U.S. red blood cell demand at around 36,000 units, and the American Red Cross reports close to 16 million blood components transfused annually in the country. Every one of those units has to pass through typing, screening, and cross-matching before it reaches a patient, and that repeat-testing cycle is what keeps reagent and kit demand climbing in lockstep with donation volume.

Download a free sample report or claim your copy of this full market intelligence report

Key Segmentation

Rather than reading as four disconnected categories, the market's segmentation tells a single, coherent story about where the money actually flows: consumables, not equipment, are the engine.

On the product side, reagents & kits captured 66.24% of 2022 revenue and are also the fastest-growing product category at a 6.1% CAGR — an unusually rare combination where the largest segment is also the fastest-expanding one. That pairing matters because it signals a market driven by recurring, transactional demand rather than one-time capital equipment purchases. Every screened unit of blood consumes a fresh reagent; instruments get bought once and used for years. Recent product activity reinforces this: Ortho Clinical Diagnostics' ORTHO VISION Swift and VISION Max Swift analyzers (April 2021) and Mindray's BC-700 series (March 2022) both point to vendors investing in higher-throughput, higher-security testing platforms, even as the underlying revenue keeps concentrating in the disposables that run through them.

By application, disease screening led with roughly 60.4% share in 2022 and the fastest-growing CAGR at 6.0%, ahead of blood grouping. This isn't a coincidence — it maps directly onto the rising concern around transfusion-transmitted infections (TTIs) such as Hepatitis B and HIV, particularly in lower-income regions where pre-transfusion screening infrastructure is still being built out.

By end-use, blood banks held the largest share at 39.22% and the fastest CAGR at 6.2%, ahead of hospitals and standalone diagnostic laboratories, reflecting how much of the testing burden — blood typing, Rh typing, antibody screening, infectious disease panels — happens before blood ever leaves the collection facility rather than at the point of transfusion.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Key Drivers & Restraints

The demand side of this market is unusually well-documented with real-world triggers rather than abstract growth narratives. Trauma and accident volume is one of the starkest: the WHO estimates roughly 1.3 million road-accident deaths annually, alongside 20–50 million non-fatal injuries, a huge share of which involve emergency transfusion. Surgical demand compounds this — cardiopulmonary bypass procedures, neurosurgery, and chronic bleeding disorders all lean on platelet transfusions as a matter of routine, not exception.

Regulatory momentum is quietly one of the more underappreciated growth levers here. India's Drug Controller General now requires blood bank cold-chain equipment to meet medical-grade, Class B certification standards, and the State Blood Transfusion Council has mandated hepatitis B and C case reporting from registered blood banks — the kind of compliance-driven demand that tends to be far stickier than discretionary healthcare spending, because it isn't optional. Donation-awareness campaigns are moving the needle too: WHO data shows global blood donations near 118.5 million units, with voluntary unpaid donations climbing by 10.7 million between 2008 and 2018, while India's e-RaktKash initiative alone ran roughly 53 donation campaigns in a single six-month window.

The clearest restraint is the one the market has already lived through: COVID-19. Social-distancing mandates gutted donation drives worldwide, and the Pan American Health Organization recorded a 20% drop in blood donations across Latin America and the Caribbean during the pandemic's peak. That episode is a useful reminder that this market's biggest vulnerability isn't demand — it's supply-side donor availability, which can be disrupted by anything that keeps people away from donation centers.

Key Industry Players

North America leads the regional landscape with a 39.59% revenue share in 2022, anchored by the U.S., where dense testing infrastructure and strong reimbursement frameworks support consistent screening volumes. The more interesting regional story, though, is Asia Pacific, forecast to grow fastest at a 7.1% CAGR through 2030 — a rate outpacing the global average by more than a full point, driven by rising TTI prevalence and expanding donation infrastructure. India illustrates this well: the Ministry of Health and Family Welfare recorded roughly 1.58 million blood units collected in the country since January 2022 alone.

Competitively, the field is led by a mix of diagnostics majors and blood-transfusion specialists — Grifols, Bio-Rad Laboratories, F. Hoffmann-La Roche, Quotient Limited, Abbott, Ortho Clinical Diagnostics, bioMérieux, Siemens Healthcare, MedGenome, and Beckman Coulter, among others. What differentiates the leaders isn't scale alone but where they're placing R&D bets: Quotient's MosaiQ platform stands out as the first fully automated system combining blood grouping and TTI screening in one workflow, a genuine step-change from running these as separate tests. MedGenome's February 2023 launch of an FSHD1 genetic screening test signals a parallel trend — diagnostics players extending beyond classic blood-bank testing into genetic screening adjacent to transfusion medicine. That convergence of automation and genomics is arguably the most important undercurrent in this market right now: the companies winning share aren't just making reagents cheaper, they're compressing multiple tests into single automated platforms, which is where the next leg of margin and differentiation will come from.

Explore the full list of profiled companies operating in this market with recent strategic initiatives